Wealth Enhancement Advisory Services
CRSP icon

Wealth Enhancement Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Sell
25,163
-1,514
-6% -$79.8K ﹤0.01% 1865
2026
Q1 		$1.32M Sell
26,677
-62,679
-70% -$3.31M ﹤0.01% 1635
2025
Q4 		$5.2M Buy
89,356
+5,340
+6% +$320K 0.01% 996
2025
Q3 		$5.93M Buy
84,016
+1,409
+2% +$80.9K 0.01% 868
2025
Q2 		$4.31M Sell
82,607
-11,493
-12% -$445K 0.01% 964
2025
Q1 		$3.2M Buy
94,100
+66,789
+245% +$2.83M 0.01% 1019
2024
Q4 		$1.07M Sell
27,311
-2,930
-10% -$138K ﹤0.01% 1498
2024
Q3 		$1.42M Sell
30,241
-1,657
-5% -$84.1K ﹤0.01% 1220
2024
Q2 		$1.72M Buy
31,898
+18,239
+134% +$1.05M ﹤0.01% 1050
2024
Q1 		$931K Sell
13,659
-492
-3% -$35.2K ﹤0.01% 1269
2023
Q4 		$886K Buy
14,151
+3,781
+36% +$209K ﹤0.01% 1219
2023
Q3 		$471K Buy
+10,370
New +$536K ﹤0.01% 1462

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wealth Enhancement Advisory Services's CRSP Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its CRISPR Therapeutics (CRSP) stake by 5.7% in Q2 2026, selling an estimated $79.8K and leaving 25,163 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1865.

Wealth Enhancement Advisory Services first reported a position in CRSP in Q3 2023 and has held it in 12 quarters since. The position peaked at $5.93M in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Wealth Enhancement Advisory Services held 25,163 shares of CRISPR Therapeutics worth $1.34M as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 1,514 CRISPR Therapeutics shares in Q2 2026, an estimated $79.8K.
  • CRISPR Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #1865 holding.
  • Wealth Enhancement Advisory Services first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Wealth Enhancement Advisory Services's CRISPR Therapeutics position peaked at $5.93M in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.